Abstract
Conventional liposomal drug delivery has been associated with obvious limitations, such as a rapid absorption by the recticulo-endothelial system in the liver and spleen, a short circulation time and a low therapeutic efficacy. Various modifications of liposomal drugs have been developed to prolong the duration of actions of the drugs at target sites, reduce its adverse effects and increase therapeutic index of drugs such as polymeric conjugation and polymeric fixation on the surface of a liposome. The lymphatic system is an important highway to spread the metastasis of most human cancers including breast, colon, and lung, ovarian and prostate. To eradicate those metastatic cancer cells from the lymphatic system, several efforts have been made to develop new and efficient lymphatic targeting drug delivery systems in order to achieve a high initial lymphatic uptake and lymph node localization. Recently, molecule targeting of liposome to lymphatic system may enhance therapeutic efficacy by improving the initial lymphatic uptake and the lymph nodal retention of liposomes such as the ligand-receptor and antibodies binding on the surface of liposome. This article aims to review the emerging liposomal drug, which is targeting the lymphatic system. The significant factors associated with targeting liposomal drugs will also be discussed in more detail in this review.
Keywords: Stealth liposome, targeted drug delivery system, lymphatic system, immunoliposome, metastasis, liposomal, lymphatic sys-tem, auxiliary lymph node, radiotherapy, chemotherapy, bloodstream, immune system, epidermal growth factor-2, nano-crystals, dendrimers, human immunodeficiency virus, camptothecin, doxorubicin, Liposome, dipalmitoyl-phosphatidylcholine (DPPC), phosphatidylserine, phacocytosis, phospholipid liposome, monoclonal antibodies, biotin/avidin-liposome, Adriamycin, Cholesterol, Dicetylphosphate, Egg phosphatidylcholine, Egg-phosphatidylglycerol, Injected dose, Phosphatidylcholine, Vascular endothelial growth factors
Current Cancer Drug Targets
Title: Molecular Targeting of Liposomal Nano-Particles to Lymphatic System
Volume: 11 Issue: 2
Author(s): Nguyen-Van Cuong and Ming-Fa Hsieh
Affiliation:
Keywords: Stealth liposome, targeted drug delivery system, lymphatic system, immunoliposome, metastasis, liposomal, lymphatic sys-tem, auxiliary lymph node, radiotherapy, chemotherapy, bloodstream, immune system, epidermal growth factor-2, nano-crystals, dendrimers, human immunodeficiency virus, camptothecin, doxorubicin, Liposome, dipalmitoyl-phosphatidylcholine (DPPC), phosphatidylserine, phacocytosis, phospholipid liposome, monoclonal antibodies, biotin/avidin-liposome, Adriamycin, Cholesterol, Dicetylphosphate, Egg phosphatidylcholine, Egg-phosphatidylglycerol, Injected dose, Phosphatidylcholine, Vascular endothelial growth factors
Abstract: Conventional liposomal drug delivery has been associated with obvious limitations, such as a rapid absorption by the recticulo-endothelial system in the liver and spleen, a short circulation time and a low therapeutic efficacy. Various modifications of liposomal drugs have been developed to prolong the duration of actions of the drugs at target sites, reduce its adverse effects and increase therapeutic index of drugs such as polymeric conjugation and polymeric fixation on the surface of a liposome. The lymphatic system is an important highway to spread the metastasis of most human cancers including breast, colon, and lung, ovarian and prostate. To eradicate those metastatic cancer cells from the lymphatic system, several efforts have been made to develop new and efficient lymphatic targeting drug delivery systems in order to achieve a high initial lymphatic uptake and lymph node localization. Recently, molecule targeting of liposome to lymphatic system may enhance therapeutic efficacy by improving the initial lymphatic uptake and the lymph nodal retention of liposomes such as the ligand-receptor and antibodies binding on the surface of liposome. This article aims to review the emerging liposomal drug, which is targeting the lymphatic system. The significant factors associated with targeting liposomal drugs will also be discussed in more detail in this review.
Export Options
About this article
Cite this article as:
Cuong Nguyen-Van and Hsieh Ming-Fa, Molecular Targeting of Liposomal Nano-Particles to Lymphatic System, Current Cancer Drug Targets 2011; 11 (2) . https://dx.doi.org/10.2174/156800911794328439
DOI https://dx.doi.org/10.2174/156800911794328439 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Overview of microRNA Target Analysis Tools
Current Bioinformatics TRAIL: A Sword for Killing Tumors
Current Medicinal Chemistry Obesity and Asthma
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Advances in the Pharmacologic Treatment of Hepatocellular Carcinoma
Current Clinical Pharmacology CpG Island Methylation in Precursors of Gastrointestinal Malignancies
Current Molecular Medicine Noninvasive Assessment of Cytokines in Occupational Respiratory Diseases
Recent Patents on Inflammation & Allergy Drug Discovery MicroRNAs: Modulators of Cell Identity, and their Applications in Tissue Engineering
MicroRNA Effect of Low Molecular Weight Heparins and Fondaparinux Upon Thrombin Generation Triggered by Human Pancreatic Cancer Cells BXPC3
Current Vascular Pharmacology TRPA1 and TRPM8 Receptors May Promote Local Vasodilation that Aggravates Oxaliplatin-Induced Peripheral Neuropathy Amenable to 17β-Estradiol Treatment
Current Neurovascular Research Vanilloid Receptor Antagonists: Emerging Class of Novel Anti-Inflammatory Agents for Pain Management
Current Pharmaceutical Design Na<sup>+</sup>/K<sup>+</sup> ATPase Inhibitors in Cancer
Current Drug Targets KRAS Mutation Testing of Colorectal Cancer for Anti-EGFR Therapy: Dogmas Versus Evidence
Current Cancer Drug Targets Discovery of Novel Regulatory Peptides by Reverse Pharmacology: Spotlight on Chemerin and the RF-amide Peptides Metastin and QRFP
Current Protein & Peptide Science Phosphoinositide 3-Kinases as Targets for Therapeutic Intervention
Current Pharmaceutical Design Patent Annotations
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Overcoming Resistance of Glioblastoma to Conventional Cytotoxic Therapies by the Addition of PARP Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Sphingolipid Signaling and Hematopoietic Malignancies: To the Rheostat and Beyond
Anti-Cancer Agents in Medicinal Chemistry FoxO1 Inhibitors: The Future Medicine for Metabolic Disorders?
Current Diabetes Reviews Development of New ELISA with High Sensitivity and Selectivity for Bioanalysis of Bevacizumab: A Monoclonal Antibody Used for Cancer Immunotherapy
Current Analytical Chemistry Advances in the Development of Anticancer HSP-based Vaccines
Current Medicinal Chemistry